Evaluation of Perioperative Management of Curative Anticoagulants in the Geriatric Perioperative Unit in Patient Hospitalized for Femoral Neck Fracture.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05286671

Acronym

ANTICOGER

Enrollment

Registered

2022-03-18

Start date

2022-02-01

Completion date

2022-03-11

Last updated

2022-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulants; Circulating, Hemorrhagic Disorder, Femoral Neck Fractures

Keywords

older patients, anticoagulant, femoral neck fractures, clinical pharmacy service

Brief summary

Pilot study to evaluate the management of curative anticoagulant prescriptions pre- and postoperatively in elderly patients hospitalized for femoral neck fracture.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

75 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient 75 years or older * Hospitalized in the geriatric perioperative unit for a femoral neck fracture between 18/11/2019 and 30/06/2021 * Treated with a curative anticoagulant at entry * Patient enrolled in or receiving a social security plan

Exclusion criteria

* Orthopedic patient housed in the geriatric perioperative unit * Patient who objected to the use of their data

Design outcomes

Primary

Measure	Time frame	Description
Rate of compliance with the recommendations for direct oral anticoagulants (DOAC)..	Day 0	Rate of compliance with the french working group on perioperative haemostasis (GIHP) recommendations for DOACrecommendations for DOA.
Rate of compliance with the recommendations for vitamin K antagonists (VKA).	Day 0	Rate of compliance with the french health authority (HAS) recommendations for VKA

Secondary

Measure	Time frame	Description
Number of pharmaceutical interventions	Day 0	Number of pharmaceutical interventions regarding anticoagulant prescriptions
description of pharmaceutical interventions	Day 0	description of pharmaceutical interventions
Evaluation of the morbi-mortality	Day 0	Mortality, re-hospitalizations at 30 days, characterization of bleeding complications, characterization of thrombotic complications
Description of the evolution of the plasma dosage of DOAC and the international normalized ratio (INR) and analysis of the operative delay	Day 0	Value of preoperative DOAC plasma dosage, value of INR dosage pre- and post-op, analysis of the operative delay
description of the population	Day 0	age, weight, height, body mass index, comorbidities

Countries

France

Outcome results